

MONDAY, OCTOBER 11, 2010

7:30-8:00 **BREAKFAST**

8:00-8:10 **INTRODUCTIONS AND WELCOME**

SESSION 1-IMMUNE TARGETING OF ALL
Chair: Rick O'Reilly, MSKCC, New York, NY

8:10-8:35 *Rick O'Reilly, MSKCC, New York, NY*
Adoptive Immune Therapies Employing Antigen-Specific T Cells of Desired HLA Restriction for Treatment of Life-Threatening Viral Diseases Following HLA-Disparate Cord Blood and Adult HSC Transplants

8:35-9:00 *Hans Stauss, Royal Free Hospital, London, UK*
Engineering WT1 TCRs

9:00-9:25 *Max Topp, University of Würzburg, Germany*
Blinatumomab, A Bispecific Antibody Targeting CD19, Induces Haematological and Molecular Remissions in Patients with Various B-Cell Malignancies

9:25-9:50 *Alan Wayne, NCI, Bethesda, MD*
Anti-CD22 Immunotoxins for Acute Lymphoblastic Leukemia

9:50-10:05 **BREAK**

Session 2-Chimeric Antigen Receptor for Hematology Malignancies
Chair: Malcolm Brenner, TCH, TMH, BCM, Houston, TX

10:05-10:30 *Michel Sadelain, MSKCC, New York, NY*
Targeting B Malignancies with Autologous CD19-Targeted T Cells: The MSKCC Experience

10:30-10:55 *Barbara Savoldo, TCH, TMH, BCM, Houston, TX*
The Effects of Co-stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed CAR in Human Subjects with B-Cell Malignancies

10:55-11:20 *Carl June, University of Pennsylvania, Philadelphia, PA*
CD19 CARs: Status at the University of Pennsylvania

11:20-11:45 *Oliver Press, University of Washington, Seattle, WA*
Adoptive Immunotherapy for Indolent and Mantle Cell Lymphomas Using Genetically Modified Autologous CD20-Specific T Cells

11:45-12:15 *Panel Discussion - Future of CD19/20 Targeted CARs*

12:15-1:15

LUNCH AND POSTER SESSION

Session 3-Immune Targeting of Pediatric Solid Tumors

Chair: Crystal Mackall, NCI, Bethesda, MD

1:15-1:40

Paul Sondel, University of Wisconsin, Madison, WI

Cell-Mediated Destruction of Neuroblastoma Facilitated by Anti-GD2 Reagents CH14.18 and HU14.18-IL2

1:40-2:05

Nai-Kong Cheung, MSKCC, New York, NY

Next Generation Monoclonal Antibodies for Solid Tumors: Improving Effector Functions by Enhancing Affinities for Antigen and Fc Receptor

2:05-2:30

Crystal Mackall, NCI, Bethesda, MD

Toward Exportable Consolidative Immunotherapy for Solid Tumors

2:30-2:55

Stephan Grupp, CHOP, Philadelphia, PA

Immune Reconstitution Therapies

2:55-3:20

Stanley Riddell, FHCRC, Seattle, WA

IL15 to Support Adoptive Immunotherapy

3:20-3:35

BREAK

Session 4-Cars for Solid Tumors

Chair: Gianpietro Dotti, TCH, TMH, BCM, Houston, TX

3:35-4:00

Stephen Gottschalk, TCH, TMH, BCM, Houston, TX

T Cells Redirected Against HER2 for the Adoptive Immunotherapy of HER2-Positive Malignancies

4:00-4:25

Michael Jensen, Seattle Children's Hospital, Seattle, WA

Targeting Brain Tumors

4:25-4:50

Chrystal Louis, TCH, TMH, BCM, Houston, TX

Treatment of High Risk Neuroblastoma with Autologous T Lymphocytes Engineered to Recognize GD2

4:50-6:30

POSTER SESSION/REFRESHMENTS

TUESDAY, OCTOBER 12, 2010

7:30-8:00

BREAKFAST

Session 5-Enhancing Graft versus Leukemia for Pediatric Cancers

Chair: Rupert Handgretinger, University of Tübingen, Germany

8:00-8:25

Rupert Handgretinger, University of Tübingen, Germany
NK Cell Therapies Post-AlloSCT

8:25-8:50

Franco Locatelli, Bambino Gesù Children's Hospital, Rome, Italy
Graft vs. Leukemia

8:50-9:15

Terry Fry, NCI, Bethesda, MD
Vaccines and Allogeneic SCT

9:15-9:40

Peter Bader, University of Frankfurt, Germany
Allogeneic Stem Cell Transplantation in Children and Adolescents with Solid Tumors

9:40-10:00

Antonio Di Stasi, TCH, TMH, BCM, Houston, TX
CASPALLO: Phase I Clinical Trial of Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene after Haploidentical Stem Cell Transplantation

10:00-10:25

Peter Adamson, CHOP, COG, Philadelphia, PA
Potential Pathways for Development of Immunotherapies in COG

10:25-10:40

BREAK

Session 6-Overcoming Hurdles of Immunotherapy

Chair: Laurence Cooper, MDACC, Houston, TX

10:40-11:05

Hideho Okada, University of Pittsburgh, Pittsburgh, PA
Vaccinations Targeting Glioma-Associated Antigens (GAAs) in Pediatric Patients with Glioma

11:05-11:30

Stefaan Van Gool, Katholieke University, Leuven, Belgium
Immunotherapy for High Grade Glioma: Preclinical Research and Perspectives

11:30-11:55

Laurence Cooper, MDACC, Houston, TX
cMet Specific CAR

11:55-12:15

Rebecca Gardner, FHCRC, Seattle, WA
Zinc Finger Nuclease Mediated Disruption of Glucocorticoid Regulation in Therapeutic Human T Cells

- 12:15-12:35 *Shakeel Modak, MSKCC, New York, NY*
Suppression of Human Anti-Mouse Antibody Response by Rituximab Plus Cyclophosphamide Permits Continuation of Anti-GD2 Immunotherapy
- 12:35-12:55 *Matthias Wölfl, University of Würzburg, Germany*
Primed Tumor-Reactive Multifunctional CD62L⁺ Human CD8⁺ T-Cells for Immunotherapy
- 1:00-2:00** **LUNCH**
- SESSION 7-NK CELLS, NKT CELLS AND $\gamma\delta$ CELLS**
Chair: Dario Campana, St. Jude Children's Research Hospital, Memphis, TN
- 2:00-2:25 *Dario Campana, St. Jude Children's Research Hospital, Memphis, TN*
Engineering Natural Killer Cells
- 2:25-2:50 *Mike Verneris, University of Minnesota, Minneapolis, MN*
Adoptive Therapy with Natural Killer Cells
- 2:50-3:15 *Leonid Metelitsa, TCH, BCM, Houston, TX*
Anti-tumor Potential of Type-1 NKT Cells Against CD1d⁺ and CD1d⁻ Pediatric Tumors
- 3:15-3:40 *Claudia Rossig, University of Münster, Germany*
Activated $\gamma\delta$ T Cells for Cellular Immunotherapy of Childhood Cancer
- 3:40-3:55** **BREAK**
- Session 8-Immunotherapies: Beyond Phase I Studies**
Chair: Helen Heslop, TCH, TMH, BCM, Houston, TX
- 3:55-4:15 *Ann Leen, TCH, TMH, BCM, Houston, TX*
Most Closely HLA-Matched Allogeneic Virus Specific CTL to Treat Persistent Reactivation or Infection with Adenovirus, CMV and EBV after HSCT
- 4:15-4:40 *Catherine Bollard, TCH, TMH, BCM, Houston, TX*
Administration of Tumor-Specific Cytotoxic T Lymphocytes for Patients with EBV-Associated Lymphomas – Moving to Phase II Studies
- 4:40-5:00 *John Chen, VA Medical Center, BCM, Houston, TX*
What will complex biologicals need to do to prove themselves cost-effective?
- 5:00-5:15 *Malcolm Brenner, TCH, TMH, BCM, Houston, TX*
Closing Remarks
- 5:15** **ADJOURN**